Tumor repolarization by an advanced liposomal drug delivery system provides a potent new approach for chemo-immunotherapy
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Tumor repolarization by an advanced liposomal drug delivery system provides a potent new approach for chemo-immunotherapy
Final published version, 2.16 MB, PDF document
Immunosuppressive cells in the tumor microenvironment allow cancer cells to escape immune recognition and support cancer progression and dissemination. To improve therapeutic efficacy, we designed a liposomal oxaliplatin formulation (PCL8-U75) that elicits cytotoxic effects toward both cancer and immunosuppressive cells via protease-mediated, intratumoral liposome activation. The PCL8-U75 liposomes displayed superior therapeutic efficacy across all syngeneic cancer models in comparison to free-drug and liposomal controls. The PCL8-U75 depleted myeloid-derived suppressor cells and tumor-associated macrophages in the tumor microenvironment. The combination of improved cancer cell cytotoxicity and depletion of immunosuppressive populations of immune cells is attractive for combination with immune-activating therapy. Combining the PCL8-U75 liposomes with a TLR7 agonist induced immunological rejection of established tumors. This combination therapy increased intratumoral numbers of cancer antigen-specific cytotoxic T cells and Foxp3-T helper cells. These results are encouraging toward advancing liposomal drug delivery systems with anticancer and immune-modulating properties into clinical cancer therapy.
Original language | English |
---|---|
Article number | eaba5628 |
Journal | Science Advances |
Volume | 6 |
Issue number | 36 |
ISSN | 2375-2548 |
DOIs | |
Publication status | Published - 2020 |
Bibliographical note
Publisher Copyright:
© 2020 The Authors, some rights reserved.
ID: 269499759